The global genotyping assay market is expanding rapidly as genomics, precision medicine, molecular diagnostics, and personalized healthcare become increasingly important across healthcare and life sciences. The market is projected to grow from USD 19.4 billion in 2024 to USD 37.1 billion by 2029, registering a CAGR of 13.8% during the forecast period. Technological advancements in DNA sequencing, declining sequencing costs, the rising prevalence of genetic disorders, and increasing use of genotyping in drug discovery and development are among the major factors supporting market growth.
Genotyping assays help identify genetic variations such as single-nucleotide polymorphisms (SNPs), mutations, and other DNA variations. These capabilities are increasingly important for pharmacogenomics, diagnostics and personalized medicine, agricultural biotechnology, animal genetics, and pharmaceutical research. PCR remains a major technology in the market, while sequencing, microarrays, capillary electrophoresis, and MALDI-TOF continue to support diverse genotyping applications.
Genotyping Assay Market Size by Region and Country
The regional landscape of the genotyping assay market shows strong demand across North America, Europe, Asia Pacific, and Latin America. North America held the largest share of the global genotyping assay market in 2023, supported by advanced research infrastructure, government and private funding, growing pharmacogenomics applications, investments in DNA-based testing, and the presence of major market participants.
North America Genotyping Assay Market
North America continues to be a major market for genotyping assays, with the US representing a significant contributor to regional demand. The US genotyping assay market was valued at USD 3,908.5 million in 2024 and is projected to reach USD 8,003.7 million by 2029, representing a 15.4% CAGR. Growth is supported by precision medicine adoption, personalized genomic testing, clinical applications, and expanding insurance coverage for genetic testing.
US Genotyping Assay Market
The US genotyping assay market is benefiting from the increasing integration of genomic information into clinical workflows. Demand is expanding across clinical diagnostics, pharmacogenomics, pharmaceutical research, and personalized medicine. The country’s established healthcare infrastructure and strong genomic research ecosystem are supporting continued adoption through 2029.
Canada Genotyping Assay Market
The Canada genotyping assay market was valued at USD 807.0 million in 2024 and is expected to reach USD 1,436.7 million by 2029, growing at a 12.2% CAGR. Government support for genomic research, precision medicine initiatives, and increasing adoption of personalized healthcare are contributing to market expansion.
Europe Genotyping Assay Market
Europe represents another important regional market, supported by investments in genomic research, precision medicine, molecular diagnostics, and healthcare infrastructure. Country-level demand varies across major European economies, with the UK, Germany, France, Italy, and Spain contributing to regional growth.
Germany Genotyping Assay Market
Germany’s genotyping assay market is supported by its established healthcare and pharmaceutical ecosystem, increasing healthcare expenditure, and investment in next-generation sequencing-based diagnostic testing. MarketsandMarkets identifies higher healthcare spending and improved R&D for NGS-based diagnostic tests as important factors supporting German market development.
UK Genotyping Assay Market
The UK genotyping assay market was valued at USD 1,114.4 million in 2024 and is projected to reach USD 2,101.5 million by 2029, representing a 13.5% CAGR. Increasing integration of genomic testing into clinical practice, NHS precision medicine initiatives, biotechnology innovation, and investment in genomic infrastructure are supporting market growth.
France Genotyping Assay Market
The France genotyping assay market was valued at USD 288.0 million in 2024 and is projected to reach USD 485.3 million by 2029, advancing at an 11.0% CAGR. Precision medicine adoption, genomic research investment, personalized diagnostics, and government support for genomic medicine are key factors contributing to growth.
Italy Genotyping Assay Market
The Italy genotyping assay market was valued at USD 217.5 million in 2024 and is expected to reach USD 358.4 million by 2029, registering a 10.5% CAGR. Increasing healthcare expenditure, precision diagnostics, pharmaceutical R&D, and adoption of personalized medicine are supporting demand.
Spain Genotyping Assay Market
The Spain genotyping assay market was valued at USD 206.4 million in 2024 and is projected to reach USD 334.1 million by 2029, growing at a 10.1% CAGR. Growth is being supported by the country’s healthcare infrastructure, precision medicine initiatives, oncology applications, and pharmacogenomics.
Asia Pacific Genotyping Assay Market
Asia Pacific is emerging as an important growth region for genotyping assays, supported by increasing pharmaceutical R&D activities, genomic research investments, healthcare modernization, and growing adoption of precision medicine. China, Japan, and India are particularly important markets within the region. MarketsandMarkets identifies Asia Pacific as having strong growth potential because of increasing pharmaceutical R&D and investments by biopharmaceutical companies in emerging economies.
China Genotyping Assay Market
The China genotyping assay market was valued at USD 724.5 million in 2024 and is forecast to reach USD 1,647.7 million by 2029, representing a 17.9% CAGR. Government-backed precision medicine initiatives, genomic research investments, healthcare modernization, and increasing adoption of genetic diagnostics are supporting market expansion.
Japan Genotyping Assay Market
The Japan genotyping assay market was valued at USD 509.9 million in 2024 and is projected to reach USD 1,191.5 million by 2029, growing at an 18.5% CAGR. Advanced healthcare infrastructure, an aging population, precision medicine investments, and increasing demand for molecular diagnostics are important growth factors.
India Genotyping Assay Market
The India genotyping assay market was valued at USD 226.9 million in 2024 and is expected to reach USD 494.2 million by 2029, registering a 16.8% CAGR. Rising awareness of genetic disorders, increasing precision medicine adoption, expanding healthcare infrastructure, government-supported genomic research, and India’s pharmaceutical and clinical research ecosystem are driving demand.
Latin America Genotyping Assay Market
Latin America is also witnessing increasing adoption of genomic technologies as healthcare systems modernize and precision medicine becomes more prominent. Brazil represents an important market in the region.
Brazil Genotyping Assay Market
The Brazil genotyping assay market was valued at USD 201.8 million in 2024 and is projected to reach USD 374.6 million by 2029, representing a 13.2% CAGR. Healthcare modernization, growing precision medicine adoption, and increased investment in genomic research are contributing to market expansion.
Mexico Genotyping Assay Market
Mexico is included among the key country markets covered in the MarketsandMarkets genotyping assay market analysis. Demand is supported by expanding molecular diagnostics, healthcare modernization, and increasing adoption of genomic technologies across clinical and research applications. The detailed country analysis covers Mexico across product and service, technology, application, and end-user segments.
Key Growth Drivers of the Genotyping Assay Market
Several factors are expected to influence the genotyping assay market through 2029:
- Advancements in DNA sequencing technologies and declining sequencing costs
- Rising prevalence of genetic disorders
- Increasing adoption of precision medicine and personalized healthcare
- Growing importance of genotyping in drug discovery and development
- Rising demand for pharmacogenomics
- Increasing use of bioinformatics for genomic data analysis
- Expanding applications in animal genetics and agricultural biotechnology
- Increasing investments in genomic research and national sequencing initiatives
Key Companies in the Genotyping Assay Market
Major companies operating in the genotyping assay market include Thermo Fisher Scientific Inc., Illumina, Inc., Danaher Corporation, QIAGEN, and Eurofins Scientific, along with other global players. These companies are active across genotyping instruments, reagents and kits, sequencing technologies, molecular diagnostics, and genomic analysis solutions.
The global genotyping assay market is expected to reach USD 37.1 billion by 2029, growing at a 13.8% CAGR from 2024 to 2029. North America currently represents the largest regional market, while countries across Asia Pacific—including China, Japan, and India—are recording strong growth rates. Expanding precision medicine, declining sequencing costs, genomic research investments, and wider clinical and pharmaceutical applications are expected to continue supporting the global genotyping assay market through 2029.
